Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Risankizumab in pediatric moderate to severe active ulcerative colitis
CTR20262418Phase 3Active
- Sponsor
- AbbVie Inc.
- Start
- Aug 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of risankizumab in autoimmune colitis, sponsored by AbbVie Inc.. Started Aug 2025; status: active.
02
Drugs
risankizumab
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on CTR20262418.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20262418.